Nimodipine Reappraised: An Old Drug with a Future
Autor: | Claude W. Shuttleworth, R. L. Macdonald, Andrew P. Carlson, Daniel Hänggi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Subarachnoid hemorrhage Traumatic brain injury subarachnoid hemorrhage Context (language use) Brain Ischemia 03 medical and health sciences 0302 clinical medicine Neuropharmacology Brain Injuries Traumatic medicine Humans Pharmacology (medical) Nimodipine Delayed cerebral ischemia vasospasm L-type calcium channel Pharmacology sustained release delivery business.industry Calcium channel Dihydropyridine Vasospasm General Medicine nimodipine medicine.disease Calcium Channel Blockers Stroke Psychiatry and Mental health 030104 developmental biology Neurology Anesthesia Brain Injuries Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery Vasoconstriction medicine.drug |
Zdroj: | Current Neuropharmacology |
ISSN: | 1875-6190 1570-159X |
Popis: | Nimodipine is a dihydropyridine calcium channel antagonist that blocks the flux of extracellular calcium through L-type, voltage-gated calcium channels. While nimodipine is FDAapproved for the prevention and treatment of neurological deficits in patients with aneurysmal subarachnoid hemorrhage (aSAH), it affects myriad cell types throughout the body, and thus, likely has more complex mechanisms of action than simple inhibition of cerebral vasoconstriction. Newer understanding of the pathophysiology of delayed ischemic injury after a variety of acute neurologic injuries including aSAH, traumatic brain injury (TBI) and ischemic stroke, coupled with advances in the drug delivery method for nimodipine, have reignited interest in refining its potential therapeutic use. In this context, this review seeks to establish a firm understanding of current data on nimodipine’s role in the mechanisms of delayed injury in aSAH, TBI, and ischemic stroke, and assess the extensive clinical data evaluating its use in these conditions. In addition, we will review pivotal trials using locally administered, sustained release nimodipine and discuss why such an approach has evaded demonstration of efficacy, while seemingly having the potential to significantly improve clinical care. |
Databáze: | OpenAIRE |
Externí odkaz: |